Benefits
LDL cholesterol: modest difference vs placebo in two brand trials
Two Wacker-funded placebo-controlled trials tested 30 mg/day. In 92 adults with mildly raised LDL, the 12-week LDL change differed from placebo by 8.5 mg/dL, mostly because LDL rose on placebo. In 30 healthy adults, LDL fell 9.4 mg/dL during a 4-week HTEssence phase, a significant difference from placebo. Total cholesterol, HDL and triglycerides did not differ from placebo.
Antioxidant markers: class evidence from natural olive hydroxytyrosol
Limited evidence: no antioxidant outcome has been published for HTEssence itself; one brand trial named oxidized LDL as its primary endpoint but did not report it. A 16-week trial of 15 mg/day hydroxytyrosol from a natural olive extract, not HTEssence, lowered oxidized LDL, protein carbonyls and 8-OHdG versus placebo in adults with overweight and prediabetes.
Mechanism of action
Free-radical scavenging (laboratory data)
Hydroxytyrosol's catechol structure lets it neutralize free radicals in laboratory tests. After swallowing it is rapidly converted to metabolites such as homovanillic acid and hydroxytyrosol sulphate, so how much direct scavenging happens in the body is not established.
Absorption confirmed in a brand trial
In the 4-week brand trial, urinary hydroxytyrosol and homovanillic acid rose clearly after HTEssence compared with placebo, showing the synthetic form is absorbed, with no difference from a natural olive extract at the same dose.
Clinical trials
Randomized, double-blind, placebo-controlled trial of 15 mg/day hydroxytyrosol from a natural olive extract for 16 weeks; the registration (NCT06295913) lists an olive extract with collaborator Genosa I+D, not HTEssence. (Moratilla-Rivera et al. 2025, Clinical Nutrition)
52 adults aged 40 to 70 with overweight and prediabetes; 49 completed.
Versus placebo, oxidized LDL (primary outcome, p = 0.045), protein carbonyls and 8-OHdG fell, total antioxidant status and GPx activity were maintained, and IL-6 was lower (p = 0.05). Lipid profile, body measures and lifestyle factors did not change. Class evidence at half the HTEssence trial dose, not a test of this synthetic ingredient.
Randomized, double-blind, placebo-controlled parallel trial of HTEssence (30 mg/day hydroxytyrosol from a 20% powder in capsules) for 12 weeks; funded by Wacker Chemie and run at a contract research site; registered DRKS00015251; journal not indexed in PubMed. (Knaub et al. 2020, Journal of Nutrition & Food Sciences)
92 adults aged 18 to 75 with mildly raised LDL cholesterol (115 to 190 mg/dL) and low to moderate cardiovascular risk; 82 in the per-protocol analysis.
The primary outcome, change in LDL cholesterol, differed from placebo by 8.5 mg/dL (p = 0.045): LDL fell 2.7 mg/dL on HTEssence (confidence interval crossing zero) while it rose 5.8 mg/dL on placebo. Total cholesterol, HDL, LDL/HDL ratio, triglycerides and blood pressure did not differ. Well tolerated.
Randomized, double-blind, placebo-controlled three-way crossover comparing HTEssence with a natural olive fruit extract, each at 30 mg/day hydroxytyrosol, for 4 weeks per phase; funded by Wacker Chemie, which supplied the products; journal not indexed in PubMed. (Siefer et al. 2018, Journal of Nutritional Medicine and Diet Care)
30 healthy adults aged 35 to 65 with normal blood lipids; 29 completed.
The stated primary outcome, oxidized LDL, is not reported in this paper. As a secondary outcome, LDL cholesterol fell 9.4 mg/dL during the HTEssence phase; versus placebo p = 0.025 in all subjects and p = 0.0003 after excluding two outliers. The olive extract did not lower LDL. Total cholesterol, HDL and triglycerides did not change; urinary markers confirmed uptake.